LRRK2 and Parkinson disease: As such BMP is an important biomarker to study LRRK2-driven pathogenic mechanisms or modulation of LRRK2 activity by therapeutics (i.e., target modulation biomarker) but does not appear to be a biomarker of progression or risk to develop PD in prodromal individuals.